Ascending to improve treatment options, outcomes, and lives

Clinical Trials

Ascendis Pharma is committed to developing a proprietary pipeline of unique products that address unmet patient needs in rare endocrine diseases. Our ongoing clinical trials for TransCon Growth Hormone and TransCon PTH are a reflection of that commitment.

TransCon Growth Hormone

More about the heiGHt Trial

More about the fliGHt Trial

TransCon PTH (parathyroid hormone)

A phase 1 clinical trial has been initiated in healthy adults to evaluate the safety, tolerability and pharmacodynamics/pharmacokinetics of TransCon PTH.

*Children <3 may be treatment-naïve.
Children <3 years of age only.
TransCon Growth Hormone and TransCon PTH are investigational products. GHD = growth hormone deficiency; hGH = human growth hormone; PTH = parathyroid hormone. The heiGHt Trial, fliGHt Trial and enliGHten Trial are sponsored by Ascendis Pharma Endocrinology Division A/S; a company in the Ascendis Pharma Group.